Showing results (71-80 of 122) with videos related to
Sort By:
Pageof 13
BMJ Open|January 10, 2014
Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocolPelle L Ishøy, Filip K Knop, Brian V Broberg, et al.Cortex; a Journal Devoted to the Study of the Nervous System and Behavior|May 2, 2021
Associations between cognition and white matter microstructure in first-episode antipsychotic-naïve patients with schizophrenia and healthy controls: A multivariate pattern analysisMarie B Thomas, Jayachandra M Raghava, Christos Pantelis, et al.Geroscience|June 1, 2022
Subclinical cognitive deficits are associated with reduced cerebrovascular response to visual stimulation in mid-sixties menMark Bitsch Vestergaard, Ulrich Lindberg, Maria Højberg Knudsen, et al.Schizophrenia Research|September 3, 2020
Cognitive remediation plus standard treatment versus standard treatment alone for individuals at ultra-high risk of developing psychosis: Results of the FOCUS randomised clinical trialLouise B Glenthøj, Lise S Mariegaard, Birgitte Fagerlund, et al.Geroscience|November 21, 2024
Cognitive aging and reserve factors in the Metropolit 1953 Danish male cohortMostafa Mehdipour Ghazi, Olalla Urdanibia-Centelles, Aftab Bakhtiari, et al.Journal of the American Academy of Child and Adolescent Psychiatry|March 13, 2019
Cardiometabolic Adverse Effects and Its Predictors in Children and Adolescents With First-Episode Psychosis During Treatment With Quetiapine-Extended Release Versus Aripiprazole: 12-Week Results From the Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (TEA) TrialKarsten Gjessing Jensen, Christoph U Correll, Ditte Rudå, et al.Acta Psychiatrica Scandinavica|August 1, 2021
Global fractional anisotropy predicts transition to psychosis after 12 months in individuals at ultra-high risk for psychosisTina D Kristensen, Louise B Glenthøj, Karen Ambrosen, et al.Psychopharmacology|November 30, 2017
Change and dispersion of QT interval during treatment with quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: results from the TEA trialKarsten Gjessing Jensen, Stefan Gärtner, Christoph U Correll, et al.Schizophrenia Research|February 8, 2025
Neurodevelopment within the first three years of life does not predict psychotic experiences at age 10: A prospective cohort studyMaría Hernández-Lorca, Martin Køster Rimvall, Jens Richardt Møllegaard Jepsen, et al.Psychological Medicine|July 6, 2019
Cognitive reserve attenuates age-related cognitive decline in the context of putatively accelerated brain ageing in schizophrenia-spectrum disordersTamsyn E Van Rheenen, Vanessa Cropley, Birgitte Fagerlund, et al.Pageof 13